News | Heart Valve Technology | January 16, 2017

Minneapolis Heart Institute Continues Early Feasibility Trial With Tendyne Device for Smaller Hearts

Tendyne Mitral valve

The Tendyne mitral valve being implanted. 

Tendyne Mitral valve anchoring system

An illustration showing the Tendyne mitral valve transapical anchoring system.

January 16, 2017 – In 2015, researchers and physicians at the Minneapolis Heart Institute Foundation (MHIF) were the first in the U.S. to conduct a transcatheter mitral valve replacement using a device from Abbott called the Tendyne Bioprosthetic Mitral Valve. This was part of a study to learn if such a device could help patients with damaged mitral valves who were not good candidates for conventional surgery. At that time, only one size of the device was available, and it was too large for patients with smaller hearts, including some women, because those smaller hearts did not have as much room for the valve. To address this issue, Tendyne developed a modified device, and MHIF recently used it to treat a female patient. MHIF was also the first in the U.S. to implant the new valve in a FDA-approved compassionate care case.

What differentiates the second-generation valve from the first version are subtle changes to the shape and dimensions of the valve's outer sealing frame, making it potentially more viable for patients with smaller hearts. These changes were intended to allow more patients to be treated than was previously possible. 
 
“We were turning away too many patients who weren't able to be treated with the original device,” said Dan Mans, the vice president of clinical and therapy development for Abbott's Tendyne business, the need for the smaller device became clear during the early trials for the first version. “The new version is intended to provide therapy for more patients. Once we developed it, we went back to patients who previously failed the screening and found many could be treated with the new device.”

 The principal investigators for the study being conducted at MHIF are Paul Sorajja, M.D., Saeid Farivar, M.D. and Wesley Pedersen, M.D.

“This new less-invasive technology could offer hope for improved quality of life to patients who have very limited options today," Pedersen said. "Transcatheter valve replacement treatment has proven very successful for aortic valve procedures, and we are hoping to see similar success for patients with poorly functioning mitral valves. Having an additional size of valve helps us track results with a larger patient population.” MHIF leads the U.S. in enrollments for the study, having done the most Tendyne implants in the world, with 16 implants completed.
 
Mitral regurgitation (MR) is a debilitating, progressive and life-threatening disease in which a leaky mitral valve causes a backward flow of blood in the heart. In the U.S., MR affects nearly one in 10 people age 75 and older. These patients often have difficulty with everyday activities, such as climbing stairs, and may require long periods of rest due to fatigue. Left untreated, the condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly. Medications for the condition are limited to symptom management and do not stop the progression of the disease. Open heart mitral valve surgery is the standard treatment, but many people are not healthy enough to undergo this treatment.

For more information: www.mplsheart.org

 

Related Content

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

Feature | Heart Valve Technology | July 08, 2021
July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valv
The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.

News | Heart Valve Technology | June 02, 2021
June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its...
If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.